ENDPOINTS NEWS13h
Break­ing: Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO
Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...
BioSpace20h
MyoKardia Alumni Launch Kardigan with $300M to Tackle Heart Disease
After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...
pharmaphorum22h
Ouro makes debut with $120m for autoimmune disease TCEs
A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...
ENDPOINTS NEWS23h
An­oth­er biotech scoops up as­set from Chi­na-based Keymed and nabs $180M
Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...
Ouro Medicines Launches To Define The Future Of Treatment For People With Immune-Mediated Diseases
Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...